RGD Reference Report - Expression of bone morphogenetic proteins, the subfamily of the transforming growth factor-beta superfamily, in renal cell carcinoma. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Expression of bone morphogenetic proteins, the subfamily of the transforming growth factor-beta superfamily, in renal cell carcinoma.

Authors: Kwak, C  Park, YH  Kim, IY  Moon, KC  Ku, JH 
Citation: Kwak C, etal., J Urol. 2007 Sep;178(3 Pt 1):1062-7. Epub 2007 Jul 20.
RGD ID: 1643589
Pubmed: PMID:17644140   (View Abstract at PubMed)
DOI: DOI:10.1016/j.juro.2007.05.005   (Journal Full-text)

PURPOSE: We investigated the potential expression of bone morphogenetic proteins, including bone morphogenetic protein-4, 6 and 7, the largest subfamily of the transforming growth factor-beta superfamily, in patients with renal cell carcinoma and identified its potential prognostic value in terms of clinical outcome. MATERIALS AND METHODS: Immunohistochemical staining of paraffin sections for bone morphogenetic protein was performed in 185 cases of renal cell carcinoma using a streptavidin-peroxidase procedure. Relationships between bone morphogenetic protein expression, and clinicopathological characteristics and clinical outcome were analyzed. RESULTS: The positive rate of bone morphogenetic protein-4, 6 and 7 expression in renal cell carcinoma was 44.3%, 20.0% and 34.1%, respectively. No statistically significant association was observed between bone morphogenetic protein immunoreactivity and age, Eastern Cooperative Oncology Group performance status and T stage. However, bone morphogenetic protein-4 expression correlated with Fuhrman grade (p = 0.034). The bone morphogenetic protein-7 expression rate was higher in female than in male patients (p = 0.007). The bone morphogenetic protein expression rate in nonclear types including chromophobe or papillary type was higher than that in the clear cell type (each p <0.001). Disease-free survival was higher in patients with bone morphogenetic protein-7 expression than in those without expression (log rank test for trend p = 0.0273). CONCLUSIONS: In the current study, the correlation between the expression of bone morphogenetic proteins and histological subtype was found. In addition, our findings suggest that bone morphogenetic protein-7 expression may be considered a new prognostic factor in renal cell carcinoma.



RGD Manual Disease Annotations    Click to see Annotation Detail View
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
BMP4Humanrenal cell carcinoma severityIEP  RGD 
BMP7Humanrenal cell carcinoma disease_progressionIEP  RGD 
Bmp4Ratrenal cell carcinoma severityISOBMP4 (Homo sapiens) RGD 
Bmp4Mouserenal cell carcinoma severityISOBMP4 (Homo sapiens) RGD 
Bmp7Ratrenal cell carcinoma disease_progressionISOBMP7 (Homo sapiens) RGD 
Bmp7Mouserenal cell carcinoma disease_progressionISOBMP7 (Homo sapiens) RGD 

Objects Annotated

Genes (Rattus norvegicus)
Bmp4  (bone morphogenetic protein 4)
Bmp7  (bone morphogenetic protein 7)

Genes (Mus musculus)
Bmp4  (bone morphogenetic protein 4)
Bmp7  (bone morphogenetic protein 7)

Genes (Homo sapiens)
BMP4  (bone morphogenetic protein 4)
BMP7  (bone morphogenetic protein 7)


Additional Information